Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy.
Photodynamic therapy (PDT) has been studied and applied to various disease processes. The potential of PDT for selective destruction of target tissues is especially appealing in cardiovascular disease, in which other existing interventional tools are somewhat nonselective and carry substantial risk of damage to the normal arterial wall. Enthusiasm for photoangioplasty (PDT of vascular de novo atherosclerotic and, potentially, restenotic lesions) is fueled by more effective second-generation photosensitizers and technological advances in endovascular light delivery. This excitement revolves around at least 4 significant attributes of light-activated therapy: the putative selectivity and safety of photoangioplasty, the potential for atraumatic and effective debulking of atheromatous plaque through a biological mechanism, the postulated capability to reduce or inhibit restenosis, and the potential to treat long segments of abnormal vessel by simply using fibers with longer light-emitting regions. The available nonclinical data, coupled with the observations of a new phase I trial in human peripheral atherosclerosis, suggest a promising future for photoangioplasty in the treatment of primary atherosclerosis and prevention of restenosis.
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. rockson@leland.stanford.edu
S G
SG
Rockson
D P
DP
Lorenz
W F
WF
Cheong
K W
KW
Woodburn
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006083:Graft Occlusion, Vascular / Q000188:drug therapy; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D010778:Photochemotherapy / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use*
D006415:Hematoporphyrins; D017319:Photosensitizing Agents